以VM26为主的联合化疗方案治疗进展期胃癌的临床研究

目的观察以VM26为主的联合化疗方案对进展期胃癌的疗效和毒副反应。方法122例进展期胃癌随机分为VLF组（VM26，甲酰四氢叶酸，5－FU）和VF组（VM26，5－FU），分别观察其疗效和毒副反应。结果VLF组CR6例，PR34例，有效率46％，VF组CR2例，PR9例，有效率31．4％，但无统计学差异；进行3～4个疗程者有效率为51．6％，高于2个疗程的38．5％，但无统计学差异；毒副反应有厌食，恶心呕吐等消化道反应和骨髓抑制等，但患者可以耐受。结论VM26对进展期胃癌有较好的疗效。

A CLINICAL STUDY OF COMBINATION CHEMOTHERAPY MAINLY INCLUDING VM26 FOR ADVANCED GASTRIC CANCER

To observe the efficacy and the adverse effects of combination chemotherapy mainly includingVM26 for advanced gastric cancer. METHODS 122 cases of advanced gastric cancer were randomly allocated intogroup VLF (VM26. Leucovorin. 5-FU) and group VF (VM26. 5-FU). and the efficacy and adverse effects of theseregimens were observed respectively. RESULTS There were 6 CR and 34 PR in group VLF. the response ratewas 46%, while 2 CR and 9 PR in group VF, the response rate was 31. 4%, no significant difference was foundbetween the two groups. Although the difference was not significant, the response rate of 51. 6% in the patientswho received 3-4 courses was higher than that of 38. 5% in the patients who received 2 courses. The adverse effects including gastrointestinal reaction, such as nausea, vomiting and bone marrow depression etc. were found,but were tolerable. CONCLUSION VM26 was effective in the treatment of advanced gastric cancer.